Article Text

Download PDFPDF
Review: terazosin improves urological symptoms in benign prostatic hyperplasia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In men with benign prostatic hyperplasia (BPH), does the non-uroselective α blocker terazosin improve urological symptoms?

Data sources

Studies were identified by searching Medline (1966–2001), the Cochrane Library, the Prostatic Diseases and Urologic Malignancies Group specialised register; and reviewing bibliographies of relevant studies and reviews.

Study selection

Studies were selected if they were randomised controlled trials (RCTs) in any language comparing terazosin with placebo, phytotherapy, or pharmacological or surgical therapies in men with symptomatic BPH and had a treatment duration ≥4 weeks.

Data extraction

2 reviewers independently extracted data on methodological quality, study design, patient characteristics, enrolment criteria, outcomes, adverse effects, and dropouts. The main outcome was change in urological symptoms measured by validated symptom scores (Boyarsky Symptom Score, American Urological Association [AUA], and International Prostate Symptom Score [IPSS]) (AUA and IPSS scales are identical), presented as the percentage absolute improvement from baseline. …

View Full Text


  • Source of funding: Department of Veterans Affairs Health Services Research and Development Service.

  • For correspondence: Dr T J Wilt, Minneapolis VA Center for Chronic Disease Outcomes Research, Minneapolis, MN, USA. Tim.Wilt{at}

  • Abstract and commentary also appear in ACP Journal Club.